Episode # 263 • 03 Mar 2026
Immunotherapy for Adults with RRP
Recurrent respiratory papillomatosis (RRP) has long been managed with repeated surgical debulking, sometimes requiring dozens of procedures over a lifetime. In this episode of BackTable, Dr. Aaron Friedman and guest host Dr. Stephen Schoeff discuss a major shift in care: immune-directed therapy targeting HPV 6 and 11.
Timestamps
Recurrent Respiratory Papillomatosis Foundation Position Statement on the Management of Adults With RRP
https://pubmed.ncbi.nlm.nih.gov/41543033/
Dr. Stephen Schoeff
https://healthy.kaiserpermanente.org/washington/clinicians/stephen-schoeff-6848607
Dr. Aaron Friedman
https://www.uchealth.com/en/provider-profiles/friedman-aaron-d-1609057587
You may also like
More about this episode
Dr. Friedman reviews the recent FDA approval of the Precigen product PAPZIMEOS (August 2025), a therapeutic vaccine designed to stimulate HPV-specific T-cell responses. Clinical trial data show that about half of treated adults required no additional surgeries over the following year, with many responders maintaining durable benefit for years. The conversation also covers traditional management strategies, adjuvant therapies like bevacizumab, HPV vaccination, and the evolving algorithm for adult RRP care.
00:00 - Introduction
02:13 - RRP Patient Types and Symptoms
05:06 - Adult vs Juvenile Transmission
10:46 - When to Escalate Treatment
15:40 - Immunotherapy
18:55 - Trial Enrollment, Results and Dosing Rules
26:17 - Durable Long Term Response
30:47 - Who Should Get Treated
32:34 - Logistics And Public Perception
37:50 - Future Research And Prevention
The Materials available on BackTable are provided for informational and educational purposes only and are not a substitute for the independent professional judgment of a qualified healthcare professional in diagnosing or treating patients. Any opinions, statements, or views expressed are those of the individual contributors and do not necessarily reflect those of the publisher, platform, or any affiliated organization.